V7B.F Assembly Biosciences, Inc.
- Market cap
- EUR 398M
- P/E
- 22.0x
- P/B
- 1.42x
- ROE
- -8.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is V7B.F undervalued?
Graham numberV7B.F trades 17.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Assembly Biosciences, Inc. fundamental analysis
No fundamental analysis for Assembly Biosciences, Inc. yet.
Assembly Biosciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infec…
Full company profileAssembly Biosciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Assembly Biosciences, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 6.25M | 0.00 | 7.16M | 28.5M | 72.3M | 43.2M |
| Operating Income | -91.1M | -94.1M | -64.6M | -45.4M | -12.1M | -35.4M |
| EBITDA | - | -93.6M | -64.2M | -45.3M | -12.0M | -35.3M |
| Net Income | -130M | -93.1M | -61.2M | -40.2M | -6.12M | -25.9M |
| EPS | -32 | -23 | -11 | -5.39 | -0.39 | -1.30 |
| Balance Sheet | ||||||
| Total Assets | 191M | 102M | 137M | 119M | 258M | 331M |
| Total Liabilities | 22.1M | 19.1M | 95.7M | 85.8M | 50.8M | 25.2M |
| Shareholders' Equity | 169M | 82.7M | 41.1M | 33.4M | 207M | 306M |
| Cash & Short-term Investments | 45.6M | 52.4M | 19.8M | 38.3M | 58.5M | 32.3M |
| Cash Flow | ||||||
| Operating Cash Flow | -93.4M | -84.5M | 22.7M | -51.1M | -41.1M | -75.2M |
| Capital Expenditure | 3.10M | 102K | 255K | 28.0K | 66.0K | 38.0K |
| Free Cash Flow | -96.5M | -84.6M | 22.5M | -51.1M | -41.2M | -75.2M |
| Ratios | ||||||
| ROE | -76.9% | -112.6% | -149.0% | -120.4% | -3.0% | -8.5% |
| ROA | -68.0% | -91.5% | -44.7% | -33.7% | -2.4% | -7.8% |
| Net Profit Margin | -2,076.4% | - | -854.8% | -140.9% | -8.5% | -59.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Assembly Biosciences, Inc. dividends
Assembly Biosciences, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:12 on Feb 12, 2024.
Who owns Assembly Biosciences, Inc.
- Insiders 27.99%
- Institutions 69.91%
- Public & others 2.10%
- Shares outstanding 20.4M
- Free float 9.14M
Assembly Biosciences, Inc. company profile
- Company name
- Assembly Biosciences, Inc.
- Ticker
- V7B.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Fiscal year end
- December
- Address
- Two Tower Place, South San Francisco, CA, United States, 94080
- Phone
- 833 509 4583
- Website
- assemblybio.com
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Assembly Biosciences, Inc. management
10- Mr. Jason A. Okazaki J.D.CEO, President & Director · born 1976
- Dr. William E. Delaney IV, Ph.D.Chief Scientific Officer · born 1972
- Dr. Anuj Gaggar M.D., Ph.D.Chief Medical Officer · born 1978
- Ms. Jeanette M. BjorkquistPrincipal Financial Officer, Executive Director of Accounting & Treasury · born 1987
- Mr. Shannon RyanSenior Vice President of Investor Relations, Corporate Affairs & Alliance Management
- Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHRChief Human Resources Officer
- Dr. Nicole S. White Ph.D.Chief Manufacturing Officer · born 1980
- Ms. Katie KitrinosSenior VP of Preclinical Research & Development
- Mr. Thomas E. RollinsExecutive Officer · born 1956
- Amy Figueroa C.F.A.Investor Relations Consultant